CLEC4C and systemic lupus erythematosus: The pathogenicity of pDC-derived type I IFNs in autoimmunity has been verified in recent clinical trials, wherein neutralization of type I IFN receptor subunit 1 by anifrolumab or pDC-specific blood dendritic cell antigen 2 (BDCA2) by litifilimab led to clinical remission in patients with active SLE (7, 8).